Dynavax Technologies Corporation (DVAX) Announces Resignation Of Dino Dina From Board of Directors

BERKELEY, CA -- (Marketwired) -- 10/07/14 -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that Dino Dina, M.D, has resigned from the Board of Directors. Dr. Dina was a director of the Company since 1997 and was the Company's Chief Executive Officer between 1998 and 2013.

"We are grateful for Dino's leadership and the contributions he made to Dynavax's development as a fellow Board member and during his 15-year tenure as our CEO," said Arnold Oronsky, Ph.D., Chairman of Dynavax.

Dr. Dina added, "With the recent completion of enrollment in the Phase 3 HEPLISAV-B™ clinical trial, Dynavax has achieved yet another milestone on the path to success for the company and the people who may benefit from its products."

About Dynavax

Dynavax, a clinical-stage biopharmaceutical company, discovers and develops novel vaccines and therapeutics in the areas of infectious and inflammatory diseases and oncology. Dynavax's lead product candidate is HEPLISAV-B, a Phase 3 investigational adult hepatitis B vaccine. For more information visit www.dynavax.com.

Contact:

Michael S. Ostrach
Vice President, Chief Business and Principal Financial Officer
510-665-7257 

Suggested Articles

Pillar is bankrolling a new accelerator for budding biotechs. Petri aims to serve biotech startups at the “frontier of biology and engineering.”

One of the last major, late-stage attempt at stopping Alzheimer’s using a BACE inhibitor has ended up on the trash pile with so many others.

The oligosaccharide microbiome modulator was no better than placebo at reducing lactose intolerance symptoms.